69214-33-1

Usage

Uses

8-Chloroimidazo[1,2-a]pyrazine is a useful research chemical.

Upstream product

• 6863-73-6 3-chloropyrazin-2-amine 
• 17157-48-1 bromoacetaldehyde 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 107-20-0 2-chloroethanal 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 3400-56-4 α-bromobutyraldehyde diethyl acetal 

Downstream Products

• 143591-61-1 3-bromo-8-chloro-imidazo[1,2-a]pyrazine 
• 689297-65-2 2'-fluoro-5'-(8-oxo-7,8-dihydroimidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile 
• 918545-19-4 5'-(8-chloro-imidazo[1,2-a]pyrazin-3-yl)-2'-fluoro-biphenyl-2-carbonitrile 
• 689297-63-0 2'-fluoro-5'-(8-methoxyimidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile 
• 918545-20-7 5'-(8-chloro-imidazo[1,2-a]pyrazin-3-yl)-4,2'-difluoro-biphenyl-2-carbonitrile 
• 918545-23-0 4,2'-difluoro-5'-(8-methoxy-imidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile 
• 918545-22-9 5'-(8-chloro-imidazo[1,2-a]pyrazin-3-yl)-6,2'-difluoro-biphenyl-2-carbonitrile 
• 689297-98-1 4,2'-difluoro-5'-(8-oxo-7,8-dihydroimidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile 
• 918544-48-6 6,2'-difluoro-5'-(8-oxo-7,8-dihydro-imidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile 
• 918545-44-5 6,2'-difluoro-5'-(8-methoxy-imidazo[1,2-a]pyrazin-3-yl)-biphenyl-2-carbonitrile 
• 887474-76-2 C₁₄H₁₄BrN₅ 
• 1231257-85-4 8-{[3-(trifluoromethyl)phenyl]amino}imidazo[1,2-a]pyrazine 
• 936361-36-3 3,8-dibromo-imidazo[1,2-a]pyrazine 
• 887475-39-0 3-bromo-8-methylsulfanyl-imidazo[1,2-a]pyrazine 

Relevant academic research and scientific papers

SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF

Provided are a substituted fused aromatic ring derivative, a composition containing the compound, and a use thereof. The substituted fused aromatic ring derivative is a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. The compound and the composition can be used to treat various protein tyrosine kinase-mediated diseases or disorders.

NOVEL IMIDAZO-PYRAZINE DERIVATIVES

The invention provides novel imidazo-pyrazine derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, m, n, and R1to R3 are as described herein: formula (I). Further provided are pharmace

COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators.

Selective Halogenation of Pyridines Using Designed Phosphine Reagents

Halopyridines are key building blocks for synthesizing pharmaceuticals, agrochemicals, and ligands for metal complexes, but strategies to selectively halogenate pyridine C-H precursors are lacking. We designed a set of heterocyclic phosphines that are installed at the 4-position of pyridines as phosphonium salts and then displaced with halide nucleophiles. A broad range of unactivated pyridines can be halogenated, and the method is viable for late-stage halogenation of complex pharmaceuticals. Computational studies indicate that C-halogen bond formation occurs via an SNAr pathway, and phosphine elimination is the rate-determining step. Steric interactions during C-P bond cleavage account for differences in reactivity between 2- and 3-substituted pyridines.

Alkynyl (hetero) aromatic compounds for inhibiting activity of protein kinase

The invention relates to alkynyl (hetero) aromatic compounds for inhibiting activity of protein tyrosine kinase. The invention further relates to a pharmaceutical composition containing the alkynyl (hetero) aromatic compounds, and preparation and application of the alkynyl (hetero) aromatic compounds. Specifically, the invention discloses the alkynyl (hetero) aromatic compound shown in an equation (I) and pharmaceutically acceptable salts, stereoisomers, solvates, hydrates, crystal forms, prodrugs and isotopic variants of the alkynyl (hetero) aromatic compound shown in the equation (I). The alkynyl (hetero) aromatic compounds can be used for treating and/or preventing protein tyrosine kinase-related diseases, such as preventing tumors.

Novel and selective TLR7 antagonists among the imidazo[1,2- a]pyrazines, Imidazo[1,5- a]quinoxalines, and Pyrazolo[1,5- a]quinoxalines Series

The Toll-like receptors (TLRs) 7 and 8 play an important role in the immune system activation, and their agonists may therefore serve as promising candidate vaccine adjuvants. However, the chronic immune activation by excessive TLR stimulation is a hallmark of several clinically important infectious and autoimmune diseases, which warrants the search for TLR antagonists. In this study, we have synthesized and characterized a variety of compounds belonging to three heterocyclic chemical series: imidazo[1,2-a]pyrazine, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline. These compounds have been tested for their TLR7 or TLR8 agonistic and antagonistic activities. Several of them are shown to be selective TLR7 antagonists without any TLR7 or TLR8 agonistic activity. The selectivity was confirmed by a comparative ligand-docking study in TLR7 antagonist pocket. Two compounds of the pyrazolo[1,5-a]quinoxaline series (10a and 10b) are potent selective TLR7 antagonists and may be considered as promising starting points for the development of new therapeutic agents.

SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS

The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These co

Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells

Melanoma is an aggressive form of skin cancer and it is generally associated with poor prognosis in patients with late-stage disease. Due to the increasing occurrence of melanoma, there is a need for the development of novel therapies. A new series of diarylamide and diarylurea derivatives containing imidazo[1,2-a]pyridine or imidazo[1,2-a]pyrazine scaffold was designed and synthesized to investigate their in vitro efficacy against the A375P human melanoma cell line. We found several compounds expressing submicromolar IC50 values against the A375P cells, from which 15d, 17e, 18c, 18h, 18i demonstrated the highest potencies with IC50 below 0.06 μM.

2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion

A novel series of 8-amino imidazo[1,2-a]pyrazine derivatives has been developed as inhibitors of the VirB11 ATPase HP0525, a key component of the bacterial type IV secretion system. A flexible synthetic route to both 2- and 3-aryl substituted regioisomers has been developed. The resulting series of imidazo[1,2-a]pyrazines has been used to probe the structure-activity relationships of these inhibitors, which show potential as antibacterial agents.

Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia

We report the discovery of a series of imidazo[1,2-a]pyrazine derivatives as novel inhibitors of phosphodiesterase 10A (PDE10A). In a high-throughput screening campaign we identified the imidazopyrazine derivative 1, a PDE10A inhibitor with limited select